Tandem Diabetes Care (TNDM) Short-term Investments (2013 - 2026)

Tandem Diabetes Care's Short-term Investments history runs 14 years deep, the most recent figure standing at $390.9 million for Q1 2026.

• Quarterly Short-term Investments rose 24.08% year-over-year to $390.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $390.9 million (up 24.08% YoY) and the FY2025 annual result came in at $202.0 million, down 45.26% from the prior year.
• Short-term Investments was $390.9 million for Q1 2026 at Tandem Diabetes Care, up from $202.0 million in the prior quarter.
• Across five years, Short-term Investments topped out at $541.7 million in Q1 2022 and bottomed at $202.0 million in Q4 2025.
• A 5-year average of $387.1 million and a median of $404.7 million in 2024 frame the typical range for Short-term Investments.
• Annual changes were most pronounced in 2022 — Short-term Investments soared 37.96% — and 2025, when it sank 46.46%.
• Tandem Diabetes Care's Short-term Investments stood at $444.4 million in 2022, then fell by 7.95% to $409.0 million in 2023, then fell by 9.77% to $369.1 million in 2024, then plunged by 45.26% to $202.0 million in 2025, then surged by 93.5% to $390.9 million in 2026.
• Business Quant data shows TNDM's Short-term Investments at $390.9 million in Q1 2026, $202.0 million in Q4 2025, and $227.2 million in Q3 2025.